C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 417/12 (2006.01) A61K 31/427 (2006.01) A61P 3/10 (2006.01)
Patent
CA 2370270
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride monohydrate characterised in that it: (i) provides an infra red spectrum containing peaks at 3358, 2764, 1245, 833 and 760 cm-1; and/or (ii) provides an X-ray powder diffraction (XRPD) pattern containing peaks at 15.0, 17.7, 23.0, 30.0 and 31.4 ~2.theta.; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
La présente invention concerne un monohydrate d'hydrochlorure 5-[4-[2-(N-méthyl-N-(2-pyridyl)amino)éthoxy]benzyl]thiazolidine-2,4-dione qui se caractérise en ce qu'il: (i) produit un spectre infrarouge contenant des pics à 3358, 2764, 1245, 833 et 760 cm?-1¿; et/ou (ii) produit un diagramme de diffraction de la poudre aux rayons X qui comporte des pics à 15,0; 17,7; 23,0; 30,0 et 31,4 ·2.theta.. On décrit également un procédé de préparation de ce composé, une composition pharmaceutique contenant ce même composé et l'utilisation de ce dernier en médecine.
Blackler Paul David James
Craig Andrew Simon
Giles Robert Gordon
Sasse Michael John
Gowling Lafleur Henderson Llp
Smithkline Beecham P.l.c.
LandOfFree
Novel pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel pharmaceutical will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1786333